Effect of L. Reuteri on Bowel Movements in Children (BIOWELL Study)

Not Applicable

Completed

• Conditions: Constipation
• Interventions: Drug: Placebo; Dietary Supplement: L.reuteri

• Registration Number: NCT03030664
• Lead Sponsor: Centre Hospitalier Intercommunal Creteil

Brief Summary

A randomized, multicenter, placebo-controlled, double blind study in two parallel groups testing the efficacy of daily oral supplementation with the probiotic L.reuteri DSM17938 compared to placebo in increasing the number of spontaneous bowel movements in infants and children with functional constipation.

Detailed Description

Functional constipation in infants up to 4 years of age is defined according to Rome III criteria (Hyman 2006). The diagnose must include 1 month of at least two of the following criteria: two or fewer defecations per week; at least 1 episode per week of incontinence after the acquisition of toilet skills; history of excessive stool retention; history of painful or hard bowel movements; presence of a large faecal mass in the rectum; history of large-diameter stools that may obstruct the toilet.

Accompanying symptoms may include irritability, decreased appetite and/or early satiety. The accompanying symptoms disappear immediately following passage of a large stool.

There is a growing interest for the use of probiotics in functional constipation as research suggests that probiotics could provide beneficial support in the traditional treatment arsenal although the mechanisms of actions are not completely understood.

Wu et al have demonstrated that Lactobacillus reuteri DSM 17938 may have a region-specific intestinal effect on gut motility and therefore could be beneficial in treatment of constipation

Lactobacillus reuteri DSM 17938 has shown significant favourable effects in adults (Ojetti 2014) and young children as described above (Coccorullo 2010, Olgac 2013). These studies require confirmation however. The present clinical study has been designed to strengthen the current available data that L. reuteri DSM 17938 has beneficial effects in infants and young children with functional constipation.

We hypothesize that daily oral supplementation with the probiotic Lactobacillus reuteri DSM 17938 will effectively increase the number of spontaneous bowel movements in infants/children diagnosed with functional constipation according to Rome IV.

Study Timeline

• Study First Submitted: 2017-01-23
• Study First Submitted QC: 2017-01-24
• Study First Posted: 2017-01-25
• Study Start: 2017-03-01
• Primary Completion: 2021-06-30
• Study Completion: 2021-07-30
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-09
• Last Update Posted: 2022-06-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

• Age: 6 months up to 4 years
• Suffering from functional constipation, as defined by modified Rome III criteria for children aged 4 years or less (Hyman 2006)
• Parent(s) willingness to postpone major changes in the infant feeding mode
• Parent(s) willingness and ability to fill in diary and questionnaires
• Written informed consent from parents
• Stated availability throughout the study period

Exclusion Criteria

• Chronic illness or major medical problem
• Gastrointestinal disease (including organic cause of constipation and dyschezia or history of severe fecalome)
• Intractable constipation (not responding to conventional treatment for more than 3 months)
• Gastrointestinal surgery (in the year before enrolment)
• Food allergy, lactose or gluten intolerance, as declared by parents
• Use of L. reuteri two weeks before randomisation and throughout the intervention period. If fed with infant formula, it cannot contain L. reuteri.
• Use of antibiotics two weeks before randomisation and throughout the intervention period, both infant/child and lactating mother
• If breastfeeding, use of L reuteri by the mother 2 weeks prior to enrolment
• Conventional treatment for constipation within 2 weeks before enrolment
• Medication that influences gastrointestinal motility
• Mental or behavioral disorders as judged by the investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Same formulation as probiotics, without active substance. 5 drops per day will be delivered
L.reuteri	L.reuteri	probiotics: L.reuteri produced by Biogaia 5 drops per day: 10exp(8) colony forming unit will be delivered

Primary Outcome Measures

Name	Time	Method
Change in number of spontaneous bowel movements	Week 4	Change in number of spontaneous bowel movements at week 4 compared to baseline evaluated by a bowel habit questionnaire (BQH)

Secondary Outcome Measures

Name	Time	Method
rescue medication	week 4	Total number of rescue medication during the intervention period
fecal retention	week 4	number of subjects with 3 or more than 3 stools per week and without fecal retention at the last week of the intervention period
Pain during defecation	week 8	Score of pain during defecation measured using Hick or Wong baker faces
Score of QOL	week 8	Score of quality of life measured using the PedsQL Parent family acute version
weekly number of spontaneous bowel movements	week 8	weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire

Trial Locations

Locations (5)

Hôpital J. Monod - Pavillon Femme Mère Enfant - Le Havre; 🇫🇷 Le Havre, France

CHU Robert Debré; 🇫🇷 Paris, France

Hôpital Saint Vincent-de-Paul; 🇫🇷 Lille, France

CH Sud francilien; 🇫🇷 Corbeil-Essonnes, France

CHI Creteil; 🇫🇷 Créteil, France